Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
552 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT02310321 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | completed | Phase 1 / Phase 2 | 97 | Astellas Pharma IncINDUSTRY | 3 |
| Sep 2, 2025 |
| clinicaltrials |
| NCT04047862 | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | completed | Phase 1 | 446 | BeiGeneINDUSTRY | 6 | Aug 22, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT04210219 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 7 | Aug 21, 2025 | clinicaltrials |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | enrolling by invitation | Phase 1 / Phase 2 | 52 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02099058 | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 237 | AbbVieINDUSTRY | 9 | Aug 14, 2025 | clinicaltrials |
| NCT06480240 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 117 | OBI Pharma, IncINDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT01403974 | Phase I Trial of BI 836845 for Various Solid Cancer | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07066397 | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL | recruiting | Phase 1 | 12 | TriArm Therapeutics (Taiwan) LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | completed | Phase 1 | 171 | AmgenINDUSTRY | 13 | Jul 20, 2025 | clinicaltrials |
| NCT02123823 | BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer | completed | Phase 1 | 164 | Boehringer IngelheimINDUSTRY | 10 | Jul 15, 2025 | clinicaltrials |
| NCT02204072 | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 | 120 | Boehringer IngelheimINDUSTRY | 8 | Jul 15, 2025 | clinicaltrials |
| NCT05650879 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer(HER2) | active not recruiting | Phase 1 | 198 | Enliven TherapeuticsINDUSTRY | 7 | Jul 15, 2025 | clinicaltrials |
| NCT07053904 | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | enrolling by invitation | Phase 1 | 54 | PharmaEssentiaINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07049458 | Study of CHO-A04 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 62 | Cho Pharma Inc.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT06415487 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | recruiting | Phase 1 | 30 | Acepodia Biotech, Inc.INDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT05785754 | DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 320 | DynamiCure BiotechnologyINDUSTRY | 4 | Jun 26, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT04676477 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 246 | Daiichi SankyoINDUSTRY | 4 | Jun 22, 2025 | clinicaltrials |
| NCT01696565 | PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy | completed | Phase 1 / Phase 2 | 32 | PhytoHealth CorporationINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT04866641 | Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 40 | Taivex Therapeutics CorporationINDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT04418661 | Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | terminated | Phase 1 / Phase 2 | 65 | SanofiINDUSTRY | 7 | May 29, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06540443 | Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas | recruiting | Phase 1 | 24 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06962254 | Imatinib and Trametinib for KRAS-mutated Solid Tumor | recruiting | Phase 1 | 10 | China Medical University HospitalOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | terminated | Phase 1 | 54 | Kinnate BiopharmaINDUSTRY | 6 | May 7, 2025 | clinicaltrials |
| NCT04261439 | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | terminated | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 7 | May 6, 2025 | clinicaltrials |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | terminated | Phase 1 | 62 | CelgeneINDUSTRY | 6 | Apr 29, 2025 | clinicaltrials |
| NCT03260322 | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 169 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Apr 24, 2025 | clinicaltrials |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer(SCope-D1) | terminated | Phase 1 | 18 | AstraZenecaINDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT06768268 | A Dose-Image Optimization Trial Evaluating Mannitol and Voluven as Adjuncts for Indocyanine Green(ICGMV) | enrolling by invitation | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06395090 | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | withdrawn | Phase 1 / Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Apr 8, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05267470 | A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)(FORTITUDE-201) | terminated | Phase 1 | 74 | AmgenINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials